Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) fell 8.9% during trading on Friday . The company traded as low as $34.31 and last traded at $34.33. 128,648 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 772,158 shares. The stock had previously closed at $37.69.
Analysts Set New Price Targets
A number of research analysts recently weighed in on GPCR shares. Morgan Stanley started coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They issued an "overweight" rating and a $118.00 target price for the company. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. Finally, JMP Securities dropped their target price on Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating on the stock in a report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics has a consensus rating of "Buy" and a consensus target price of $86.80.
View Our Latest Stock Analysis on Structure Therapeutics
Structure Therapeutics Trading Down 9.3 %
The company's 50 day moving average is $39.38 and its 200-day moving average is $39.79. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -46.18 and a beta of -3.23.
Institutional Investors Weigh In On Structure Therapeutics
A number of large investors have recently added to or reduced their stakes in GPCR. Sandia Investment Management LP acquired a new position in shares of Structure Therapeutics in the second quarter valued at $39,000. Assetmark Inc. boosted its holdings in shares of Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after buying an additional 719 shares during the period. Quarry LP acquired a new position in Structure Therapeutics in the 2nd quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock valued at $158,000 after acquiring an additional 1,420 shares during the period. Finally, Dearborn Partners LLC acquired a new stake in Structure Therapeutics during the third quarter worth approximately $202,000. Institutional investors own 91.78% of the company's stock.
About Structure Therapeutics
(
Get Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Read More
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
